BibTex format

author = {Tan, G and Spillane, KM and Maher, J},
doi = {10.3390/biology12081079},
journal = {Biology},
title = {The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer},
url = {},
volume = {12},
year = {2023}

RIS format (EndNote, RefMan)

AB - The family of human NKG2D ligands (NKG2DL) consists of eight stress-induced molecules. Over 80% of human cancers express these ligands on the surface of tumour cells and/or associated stromal elements. In mice, NKG2D deficiency increases susceptibility to some types of cancer, implicating this system in immune surveillance for malignancy. However, NKG2DL can also be shed, released via exosomes and trapped intracellularly, leading to immunosuppressive effects. Moreover, NKG2D can enhance chronic inflammatory processes which themselves can increase cancer risk and progression. Indeed, tumours commonly deploy a range of countermeasures that can neutralise or even corrupt this surveillance system, tipping the balance away from immune control towards tumour progression. Consequently, the prognostic impact of NKG2DL expression in human cancer is variable. In this review, we consider the underlying biology and regulation of the NKG2D/NKG2DL system and its expression and role in a range of cancer types. We also consider the opportunities for pharmacological modulation of NKG2DL expression while cautioning that such interventions need to be carefully calibrated according to the biology of the specific cancer type.
AU - Tan,G
AU - Spillane,KM
AU - Maher,J
DO - 10.3390/biology12081079
PY - 2023///
TI - The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer
T2 - Biology
UR -
VL - 12
ER -